American Bio Medica Corporation (ABMC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
American Bio Medica Corporation (ABMC) with AI Score 38/100 (Weak). American Bio Medica Corporation (ABMC) develops, manufactures, and sells rapid drug detection tests. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026American Bio Medica Corporation (ABMC) Healthcare & Pipeline Overview
American Bio Medica Corporation specializes in rapid drug detection tests, offering a range of immunoassay solutions for urine and oral fluid analysis. Operating in the medical diagnostics sector, the company serves diverse markets including rehabilitation, pain management, and workplace drug testing across the US, Europe, and Asia Pacific.
Investment Thesis
American Bio Medica Corporation operates in the niche market of rapid drug detection, which presents both opportunities and challenges. The company's negative gross margin of -21.1% and profit margin of -154.4% indicate significant operational inefficiencies that need to be addressed. Growth catalysts include expanding its product line and penetrating new geographic markets, particularly in the Asia Pacific region. However, the company's small size, with only 16 employees, and limited financial resources pose risks to its ability to compete effectively and scale its operations. Investors should closely monitor the company's ability to improve its financial performance and capitalize on growth opportunities in the drug testing market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited trading liquidity.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Gross margin of -21.1% highlights significant challenges in cost management and pricing strategy.
- Profit margin of -154.4% indicates substantial losses relative to revenue.
- Beta of -0.12 suggests the stock is less volatile than the overall market.
Competitors & Peers
Strengths
- Specialized product line of rapid drug detection tests.
- Established presence in rehabilitation, pain management, and government markets.
- Contract manufacturing capabilities.
- Proprietary OralStat drug test for oral fluid analysis.
Weaknesses
- Small company size with limited resources (16 employees).
- Negative gross and profit margins.
- Limited geographic reach compared to larger competitors.
- Dependence on the drug testing market.
Catalysts
- Upcoming: Potential new contracts with government agencies for drug testing services.
- Ongoing: Expansion of distribution network in the Asia Pacific region.
- Ongoing: Development and launch of new rapid drug detection tests.
Risks
- Potential: Increased competition from larger diagnostic companies.
- Potential: Regulatory changes affecting the drug testing market.
- Ongoing: Negative gross and profit margins impacting financial stability.
- Ongoing: Limited financial resources hindering growth initiatives.
- Potential: Low liquidity due to OTC market trading.
Growth Opportunities
- Expansion into international markets, particularly in the Asia Pacific region, where demand for drug testing is growing due to increasing urbanization and industrialization. This expansion requires strategic partnerships and regulatory approvals, but could significantly increase revenue streams. The global drug testing market is projected to reach $8.9 billion by 2027.
- Development of new drug testing products and technologies to address emerging drug threats and evolving customer needs. This includes expanding the range of detectable substances and improving the accuracy and speed of testing. Innovation in this area can provide a competitive edge and attract new customers. The market for advanced drug testing technologies is expected to grow at a CAGR of 7.5% over the next five years.
- Strengthening relationships with key customers in the rehabilitation, pain management, and government sectors to secure long-term contracts and increase sales volume. This involves providing customized solutions and excellent customer service. Building strong customer loyalty can create a stable revenue base. The rehabilitation and drug treatment market is estimated at $42 billion annually.
- Leveraging contract manufacturing services to generate additional revenue streams and diversify the company's business model. This involves utilizing existing manufacturing capabilities to produce diagnostic tests for other companies. Expanding contract manufacturing can improve capacity utilization and profitability. The global contract manufacturing market for medical devices is projected to reach $118 billion by 2028.
- Exploring opportunities in the infectious disease testing market to diversify the product portfolio and address a broader range of healthcare needs. This includes developing rapid tests for common infectious diseases and partnering with healthcare providers to offer comprehensive testing solutions. Diversification can reduce reliance on the drug testing market and create new growth avenues. The global infectious disease diagnostics market is expected to reach $27 billion by 2027.
Opportunities
- Expansion into international markets, particularly in the Asia Pacific region.
- Development of new drug testing products and technologies.
- Strengthening relationships with key customers.
- Diversification into infectious disease testing.
Threats
- Intense competition from larger diagnostic companies.
- Regulatory changes affecting the drug testing market.
- Economic downturn impacting demand for drug testing services.
- Emergence of new drug threats requiring updated testing methods.
Competitive Advantages
- Specialized expertise in lateral flow immunoassay technology.
- Established relationships with key customers in target markets.
- Proprietary product line of rapid drug detection tests.
- Contract manufacturing capabilities providing a diversified revenue stream.
About ABMC
American Bio Medica Corporation, established in 1986 and based in Kinderhook, New York, focuses on developing, manufacturing, and selling rapid drug detection tests. Originally named American Micro Media, Inc., the company rebranded in 1992 to reflect its focus on biomedical solutions. Its core business revolves around lateral flow immunoassay technology, enabling the immediate detection of drugs in urine and oral fluids. The company's product line includes Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II, which detect varying panels of drugs. American Bio Medica also offers OralStat, a drug test designed for oral fluid analysis, available in private-labeled versions. Beyond its proprietary products, the company distributes complementary products for substance abuse detection and infectious disease testing. Additionally, American Bio Medica provides contract manufacturing, assembly, and packaging services to other diagnostic companies. The company serves a diverse clientele, including rehabilitation centers, pain management clinics, government agencies, and workplace drug testing programs, with operations spanning the United States, Europe, and the Asia Pacific regions.
What They Do
- Manufactures rapid drug screening tests for urine samples.
- Produces drug testing cups that detect multiple drugs simultaneously.
- Offers drug tests in cassette platforms for point-of-care testing.
- Provides oral fluid drug tests for non-invasive drug detection.
- Distributes products for detecting substances of abuse.
- Offers products to detect certain infectious diseases.
- Provides contract manufacturing, assembly, and packaging services for diagnostic companies.
Business Model
- Manufacturing and selling rapid drug detection tests.
- Distributing complementary products for substance abuse and infectious disease detection.
- Providing contract manufacturing services to other diagnostic companies.
- Generating revenue through direct sales to rehabilitation centers, pain management clinics, government agencies, and workplaces.
Industry Context
American Bio Medica Corporation operates within the medical diagnostics industry, specifically focusing on rapid drug testing. The market is driven by increasing concerns about substance abuse, workplace safety regulations, and the need for quick and reliable drug detection methods. The competitive landscape includes larger diagnostic companies and specialized players offering similar testing solutions. American Bio Medica's success depends on its ability to differentiate its products, maintain regulatory compliance, and effectively serve its target markets.
Key Customers
- Rehabilitation and drug treatment centers.
- Pain management clinics.
- Government agencies.
- Employment and workplace drug testing programs.
Financials
Chart & Info
American Bio Medica Corporation (ABMC) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABMC.
Price Targets
Wall Street price target analysis for ABMC.
MoonshotScore
What does this score mean?
The MoonshotScore rates ABMC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jean Neff
CEO
Jean Neff serves as the CEO of American Bio Medica Corporation, leading a team of 16 employees. Information regarding her detailed career history, educational background, and previous roles is not available. However, as CEO, she is responsible for the strategic direction, operational management, and financial performance of the company.
Track Record: Due to limited information, it is difficult to assess Jean Neff's specific achievements and strategic decisions at American Bio Medica Corporation. However, under her leadership, the company continues to manufacture and sell rapid drug detection tests, serving various markets across the United States, Europe, and the Asia Pacific region.
ABMC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that American Bio Medica Corporation may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial resources, minimal trading volume, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and profitability trends.
- Check for any legal or regulatory issues.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor before investing.
- The company has been in operation since 1986.
- American Bio Medica Corporation manufactures and sells physical products.
- The company serves established markets, including rehabilitation centers and government agencies.
What Investors Ask About American Bio Medica Corporation (ABMC)
What does American Bio Medica Corporation do?
American Bio Medica Corporation specializes in the development, manufacture, and sale of rapid drug detection tests. Its products are designed for the immediate detection of drugs in urine and oral fluids, serving a variety of markets including rehabilitation centers, pain management clinics, government agencies, and workplace drug testing programs. The company's product line includes rapid drug screens, drug testing cups, and oral fluid tests, providing comprehensive solutions for substance abuse detection.
What do analysts say about ABMC stock?
As of March 15, 2026, there is no available analyst coverage for American Bio Medica Corporation (ABMC). Given its micro-cap status and OTC listing, the company may not attract significant analyst attention. Investors should conduct their own thorough research and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics, such as P/E ratio and profit margin, should be carefully analyzed in the context of the company's industry and competitive landscape.
What are the main risks for ABMC?
American Bio Medica Corporation faces several key risks, including intense competition from larger diagnostic companies, regulatory changes affecting the drug testing market, and negative gross and profit margins. The company's limited financial resources may hinder its ability to compete effectively and invest in growth initiatives. Additionally, trading on the OTC market exposes investors to liquidity risks and potential price volatility. Investors should carefully consider these risks before investing in ABMC.
What are the key factors to evaluate for ABMC?
American Bio Medica Corporation (ABMC) currently holds an AI score of 38/100, indicating low score. Key strength: Specialized product line of rapid drug detection tests.. Primary risk to monitor: Potential: Increased competition from larger diagnostic companies.. This is not financial advice.
How frequently does ABMC data refresh on this page?
ABMC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ABMC's recent stock price performance?
Recent price movement in American Bio Medica Corporation (ABMC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product line of rapid drug detection tests.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ABMC overvalued or undervalued right now?
Determining whether American Bio Medica Corporation (ABMC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ABMC?
Before investing in American Bio Medica Corporation (ABMC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record and analyst coverage.